Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Sino Biopharmaceutical (1177) Stock Price & Analysis

26 Followers

1177 Stock Chart & Stats

HK$5.56HK$0.08(-0.80%)
At close: 4:00 PM GMT+8
HK$5HK$5.5Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
HKD 5.51 - HKD 5.64
52-Week Range
HKD 4.19 - HKD 7.48
Previous Close
HKD 5.60
Volume
N/A
Average Volume (3M)
65.12M
Market Cap
HKD 98.92B
Enterprise Value
HKD 83.38B
Total Cash (Recent Filing)
HKD 27.58B
Total Debt (Recent Filing)
HKD 17.17B
Price to Earnings (P/E)
36.0
Beta
1.04
Next Earnings
Apr 01, 2027 (Est.)
EPS Estimate
0.11
Last Dividend Ex-Date
Sep 01, 2026
Dividend Yield
2.16%

Bulls Say, Bears Say

Bulls Say

Reaccelerating Revenue Growth

Improving top-line growth indicates stronger demand and commercialization across the medicine portfolio after several slower periods. If sustained, this momentum can broaden the revenue base, support operating leverage, and provide resources for continued investment in research, approvals, and market expansion.

Strong Gross Margins

Consistently high gross margins demonstrate substantial economic value in the company’s branded generic and innovative medicine portfolio. This level of product profitability provides a durable buffer for research, regulatory, and commercialization spending while helping preserve operating earnings through changing sales conditions.

Healthy Cash Generation

The rebound in operating and free cash flow strengthens the company’s ability to fund product development, commercialization, and other investments internally. Free cash flow to net income remained about 0.82, supporting the quality of reported earnings and improving financial resilience over the coming quarters.

Bears Say

Falling Net Profitability

The sharp decline in net margin shows that revenue growth is not translating into bottom-line earnings as efficiently as before. Persistent pressure could reduce reinvestment capacity, weaken returns on equity, and make future earnings less predictable even if the company maintains strong gross margins.

Rising Leverage

The year-over-year increase in debt has made the capital structure less conservative while profitability and return on equity have weakened. Higher leverage can reduce financial flexibility, increase the importance of stable earnings, and constrain the company’s ability to fund growth or absorb sustained operating pressure.

Modest Operating Cash Coverage

Although overall cash generation improved, the modest conversion of reported operating profit into operating cash indicates that working capital or non-cash items materially affect cash realization. This can make internally available funding less predictable and complicate planning for sustained investment in the product portfolio.

Sino Biopharmaceutical News

1177 FAQ

What was Sino Biopharmaceutical’s price range in the past 12 months?
Sino Biopharmaceutical lowest stock price was HK$4.19 and its highest was HK$7.48 in the past 12 months.
What is Sino Biopharmaceutical’s market cap?
Sino Biopharmaceutical’s market cap is HK$98.92B.
When is Sino Biopharmaceutical’s upcoming earnings report date?
Sino Biopharmaceutical’s next earnings report is estimated for Apr 01, 2027 (not yet confirmed), which is in 140 days.
How were Sino Biopharmaceutical’s earnings last quarter?
Sino Biopharmaceutical released its earnings results on Aug 19, 2026. The company reported HK$0.223 earnings per share for the quarter, beating the consensus estimate of HK$0.141 by HK$0.082.
Is Sino Biopharmaceutical overvalued?
According to Wall Street analysts Sino Biopharmaceutical’s price is currently Undervalued.
Does Sino Biopharmaceutical pay dividends?
Sino Biopharmaceutical pays a semiannual dividend of HK$0.07 which represents an annual dividend yield of 2.16%. See more information on Sino Biopharmaceutical dividends here
What is Sino Biopharmaceutical’s EPS estimate?
Sino Biopharmaceutical’s EPS estimate is 0.11.
How many shares outstanding does Sino Biopharmaceutical have?
Sino Biopharmaceutical has 18,682,953,000 shares outstanding.
What happened to Sino Biopharmaceutical’s price movement after its last earnings report?
Sino Biopharmaceutical reported an EPS of HK$0.223 in its last earnings report, beating expectations of HK$0.141. Following the earnings report the stock price went down -0.106%.
Which hedge fund is a major shareholder of Sino Biopharmaceutical?
Currently, no hedge funds are holding shares in HK:1177
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology